| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
17,107 |
14,901 |
$1.04M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
6,463 |
5,863 |
$262K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
1,005 |
957 |
$105K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
958 |
923 |
$96K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
1,030 |
962 |
$85K |
| 62323 |
|
397 |
378 |
$53K |
| J0585 |
Injection, onabotulinumtoxina, 1 unit |
95 |
64 |
$38K |
| 64483 |
|
216 |
183 |
$27K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
5,219 |
4,505 |
$26K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
316 |
306 |
$21K |
| 20553 |
|
267 |
246 |
$10K |
| 62321 |
|
53 |
52 |
$7K |
| 99152 |
|
618 |
483 |
$6K |
| 64615 |
|
55 |
54 |
$4K |
| 20610 |
|
129 |
100 |
$4K |
| 77002 |
|
182 |
150 |
$3K |
| 64484 |
|
41 |
39 |
$2K |
| 27096 |
|
16 |
12 |
$2K |
| 99215 |
Prolong outpt/office vis |
13 |
13 |
$2K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
14 |
13 |
$632.88 |
| 80305 |
|
750 |
670 |
$523.38 |
| G9577 |
Patients prescribed opiates for longer than six weeks |
199 |
193 |
$133.83 |
| G9578 |
Documentation of signed opioid treatment agreement at least once during opioid therapy |
204 |
196 |
$107.20 |
| G8730 |
Pain assessment documented as positive using a standardized tool and a follow-up plan is documented |
4,961 |
4,245 |
$56.89 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
1,435 |
1,175 |
$53.88 |
| G2065 |
Comprehensive care management for a single high-risk disease services, e.g. principal care management, at least 30 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month with the following elements: one complex chronic condition lasting at least 3 months, which is the focus of the care plan, the condition is of sufficient severity to place patient at risk of hospitalization or have been cause of a recent hospitalization, the condition requires development or revision of disease-specific care plan, the condition requires frequent adjustments in the medication regimen, and/or the management of the condition is unusually complex due to comorbidities |
18 |
12 |
$37.15 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
1,271 |
1,054 |
$2.78 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
7,930 |
6,833 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
365 |
342 |
$0.00 |
| 4040F |
|
589 |
551 |
$0.00 |
| G8783 |
Normal blood pressure reading documented, follow-up not required |
305 |
285 |
$0.00 |
| G9622 |
Patient not identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method |
98 |
94 |
$0.00 |
| G9584 |
Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy |
89 |
88 |
$0.00 |
| G9561 |
Patients prescribed opiates for longer than six weeks |
112 |
109 |
$0.00 |
| G9562 |
Patients who had a follow-up evaluation conducted at least every three months during opioid therapy |
123 |
120 |
$0.00 |
| 4004F |
|
33 |
26 |
$0.00 |
| G8950 |
Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented |
288 |
267 |
$0.00 |
| 1036F |
|
194 |
183 |
$0.00 |
| G9583 |
Patients prescribed opiates for longer than six weeks |
82 |
81 |
$0.00 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
39 |
37 |
$0.00 |